Skye Bioscience, Inc. will acquire Redx Pharma, granting shareholders of Redx approximately 46.17% ownership in the new entity. This Acquisition emphasizes Skye's commitment to expanding its market presence and product offerings.

Key Highlights

  • Skye Bioscience has entered into an acquisition agreement to procure Redx Pharma.
  • Post-acquisition, Redx shareholders are projected to hold around 46.17% of the combined company.
  • A concurrent financing effort aims for gross proceeds of $67.9 million in connection with the transaction.

Skye Bioscience, Inc. (NASDAQ: SKYE) is poised to strengthen its position in the healthcare market through the acquisition of Redx Pharma Limited. This Merger is designed to occur via a scheme of arrangement, contingent upon Shareholder approval from both companies. This acquisition not only facilitates growth but also enhances Skye's portfolio by integrating Redx's resources and capabilities.

Details of the Acquisition

The transaction is structured such that the current shareholders of Redx Pharma will receive shares of common stock from Skye Bioscience in exchange for their shares. The effective time of the acquisition, referred to as the "Closing," will see both sets of shareholders exchanging their shares based on the established Exchange Ratio, which will reflect pre-agreed valuations for both companies. With Redx valued at $125 million and Skye at $14.5 million, the expected distribution of shares post-acquisition clearly indicates a strategic consolidation aimed at creating a more competitive entity.

Financing Measures

In preparation for the transaction, Redx has initiated a Subscription Agreement for a series A financing, aiming to raise an aggregate of $36 million. Concurrently, Skye Bioscience plans to secure an additional Investment of $5 million from an existing investor, underlining strong financial support for the acquisition process. Together, these financing efforts will help to fulfill the target of gross proceeds totaling $67.9 million.

Such financial backing is important to ensure that the acquisition can proceed smoothly and under optimal conditions.

Shareholder Dynamics

After the transaction is consummated, it is projected that approximately 46.17% of the newly formed company will be owned by Redx's former equityholders, while Skye's pre-transaction equityholders are expected to hold around 5.38%. The remaining ownership stake will be distributed among investors engaged in the ongoing financing initiatives. This reallocation of shares signifies a transformative moment for both companies as they unite resources, potentially leading to improved operational efficiencies and enhanced market performance.

Next Steps for Skye Bioscience

Looking ahead, Skye Bioscience will spearhead a special shareholder meeting to obtain necessary approvals for the transaction. This includes endorsements for the issuance of new shares and any required amendments to company articles. The meeting is scheduled to take place on August 24, 2026, and will be key in determining the future direction of Skye Bioscience in the context of this significant acquisition.

Success in these efforts will set the stage for subsequent integration activities and operational enhancements following the transaction completion.

Peers Moving on This News